Zacks Investment Research on MSN1d
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year ...
Zacks Investment Research on MSN2d
Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.54 per share a year ago. These figures are ...